Within coronary patients, those who are affected by
|
|
- Deborah Charles
- 6 years ago
- Views:
Transcription
1 The Role of Antithrombin III in the Perioperative Management of the Patient With Unstable Angina Marco Rossi, MD, Lorenzo Martinelli, MD, Sergio Storti, MD, Michele Corrado, MD, Roberto Marra, MD Carmelita Varano, MD, and Rocco Schiavello, MD Departments of Anesthesia and Critical Care, and Hematology, Catholic University of the Sacred Heart, Rome, Italy Background. To evaluate the effectiveness of intraoperative administration of antithrombin III (AT III) to improve anticoagulation and preserve the hemostatic mechanisms during cardiopulmonary bypass (CPB) in patients with unstable angina under heparin treatment. Methods. We divided 22 patients, scheduled for coronary artery bypass grafting, into two groups. Group A (11 patients) received 3000 International Units (IU) of AT III concentrates plus heparin before aortic cannulation. Group B (11 patients) received only heparin. Blood drainage, allogeneic blood transfusions, and intraoperative activated coagulation time were recorded. Also, AT III, thrombin-antithrombin complex (TAT), fragment 1.2 (F 1.2), and D-dimers were measured during the operation and the first postoperative day. Results. Group A patients had fewer transfusions and had less chest-tube drainage. In group A, AT III levels increased after AT III concentrates administration and were always higher than in group B. In group B, F 1.2 and TAT increased significantly more after CPB and at the end of operation. Differences in D-dimers between the groups were not significant. Conclusions. Intraoperative administration of AT III concentrates allowed adequate anticoagulation during CPB and attenuated the coagulative cascade activation and the consequent consumptive coagulopathy. (Ann Thorac Surg 1999;68:2231 6) 1999 by The Society of Thoracic Surgeons Within coronary patients, those who are affected by unstable angina represent a growing share; for these patients, surgery is often the only possible choice [1]. Preoperative treatment includes heparin as the main point to prevent angina episodes and angina s most dangerous complications, acute myocardial infarction and sudden death [2 4]. Preoperative heparin therapy causes a consumption of antithrombin III (AT III) with a consequent resistance to heparin due to the deficiency of the cofactor [5 7]. The use of higher doses of heparin in these patients does not always reach the aim of an effective anticoagulation during cardiopulmonary bypass (CPB), which is proved by the inadequate ACT values obtained [8]. In this scenario, the phenomena linked to the consumption coagulopathy are amplified, causing a heavier postoperative bleeding and increased risk of surgical revision of hemostasis and allogeneic blood transfusions [9 10]. Preservation of the physiological levels of AT III in those patients who should undergo CPB seems to be the most rational and effective therapeutic approach [11 14]. The aim of this work is to evaluate the effectiveness of an intraoperative single dose of AT III concentrates in patients with unstable angina and under preoperative heparin treatment in improving anticoagulation and preserving the hemostatic mechanisms. Accepted for publication June 7, Address reprint requests to Dr Rossi, Istituto di Anestesiologia e Rianimazione, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, Rome, Italy; mrossi@edl.it. Material and Methods A total of 22 patients (21 men and 1 woman, mean age 61 years 9) affected by ischemic heart disease and unstable angina (Canadian Cardiovascular Society Grading Scale Class IV) and scheduled for elective coronary artery bypass surgery (CABG) were enrolled into the study after informed consent and approval by the local ethical committee. All patients were receiving subcutaneous heparin ranging from at least 72 hours before operation, to a maximum of 1 week. Patients studied were randomly divided into two groups: the AT III group (group A), of 11 patients and the control group (group B), of 11 patients. Exclusion criteria for the investigation were: (1) age greater than or equal to 70 years, (2) hepatic, renal diseases or congestive heart failure (CHF), (3) patients having oral anticoagulant or intravenous heparin or acetylsalicylic acid treatment, and (4) patients having intravenous nitrates because of the nitrates induced heparin resistance [15]. The anesthetic management, operative procedure, and conduct of CPB were standardized. A hollow-fiber membrane oxygenator (Monolyth, Sorin Italy) was used in all cases; CPB was always normothermic. The same surgical team performed all the operations and were not aware of the group allocation of the patients. Before CPB, AT III concentrate, 3000 International Units (IU) (Kybernin Behring, Marburg, Germany), was administered to the patients of group A in addition to the heparin, 300 U/kg (Eparina Bristol-Myers Squibb, Anagni, 1999 by The Society of Thoracic Surgeons /99/$20.00 Published by Elsevier Science Inc PII S (99)
2 2232 ROSSI ET AL Ann Thorac Surg ANTITHROMBIN III IN CORONARY SURGERY 1999;68: Italy). Only heparin (300 U/kg) was administered to the patients of the control group. An additional units of heparin were included in the bypass circuit of all patients. Celite-based activated coagulation time (ACT) was maintained at 480 seconds or greater in all patients by the addition of heparin when necessary. Heparin was neutralized by an intravenous injection of protamine sulfate (Protamina Roche, Milan, Italy) within 5 minutes after the end of CPB, in a ratio of 1.3 mg of protamine for every 100 units of total heparin administration. The following data were recorded: Duration of the operation, CPB, and aortic crossclamping Time taken between the end of CPB and the closure of the operative site Loss of fluid into the wound drainage system in the first 24 postoperative hours Amount of residual volume in the CPB circuit collected in blood transfusion bags and retransfused Amount of autologous blood withdrawn before starting CPB and retransfused after protamine administration Amount of allogeneic blood or blood products required. The indication for transfusion was defined as a hematocrit less than 22% during CPB and less than 30% in the postoperative period Use of antifibrinolytics Amount of heparin and protamine administered Surgical reopening for postoperative bleeding ACT was recorded at the following times: before induction, after administration of heparin, after the start of CPB, at the end of CPB, after administration of protamine, at the end of operation, first postoperative hour in intensive care unit (ICU). Blood samples were collected for measurement of prothrombin time (PT), activated partial thromboplastin time (aptt), and fibrinogen and platelets at the following times: before operation, end of operation, and first postoperative day. Whole blood samples were collected from a nonheparinized line of a triple-lumen central venous catheter to measure: AT III Thrombin-antithrombin complexes (TAT) Fragment 1.2 of prothrombin (F 1.2) Split products of the cross-linked fibrin (d-dimers) at the following times: before induction; after AT III concentrates administration and before start of CPB; end of CPB; end of operation; and first postoperative day. We measured AT III as heparin cofactor with a functional assay, based on the inhibition of thrombin-induced proteolysis of a specific chromogenic substrate (polypeptide-pna conjugated) (Antitrombina III, Instrumentation Laboratory Co, Lexington, KY). We measured AT III as a percentage, and reference values ranged between 70% and 120%. We measured TAT with an immunoenzymatic Table 1. Patients Characteristics photometric test (Enzyguest-TAT micro Behring, Berhingwerke AG, Marburg, Germany), with results expressed in g/ml. We measured F 1.2 with the enzyme-linked immunosorbent (ELISA) method (Thrombonostika F 1.2 sample, Organon Teknica Corp, Durham, NC) using specific monoclonal antibodies. Reference value was 1 nmol/ml. Semiquantitative determination of d-dimers was obtained using a latex agglutination test (Fibronosticon, Organon Teknica Corp, BV, Boxtel, The Netherlands). We measured d-dimers in ng/ml and a value greater than 2000 ng/ml was considered as significant. All values were expressed as mean and standard deviation. Comparisons among dichotomous variables were performed by 2 test, and Student s t test was used to compare continuous variables. The comparison between the groups was performed by two-factor ANOVA for repeated measures. ANOVA p values for intragroup (factor time) and intergroup variations (factor treatment) were reported. In case of significant differences between the two groups, the analysis was completed with Newman-Keuls test, and p values for the comparison at single times were reported. Values of p less than 0.05 were considered as significant. Results Group A: Treated with AT III Group B: Control Patients Mean age ( SD) Patients with LIMA 9 11 CABG CABG CABG CABG Distal anastomoses (mean) ATIII antithrombin III; CABG coronary artery bypass graft; LIMA left internal mammary artery. Patients characteristics with respect to age, number, and type of grafts were similar in the two groups (Table 1). Times of the operation were not significantly different in the two groups of patients (Table 2). The amount of the autologous blood withdrawn before CPB and retransfused after protamine was similar in the two groups of patients ( ml in group A; ml in group B). A similar amount of residual volume collected from the CPB circuit was retransfused in the two groups after surgery during the first 24 postoperative hours (1, ml in AT III group and 1, ml in the untreated group). None of the 22 patients needed reexploration for surgical bleeding. Only 1 patient in the group treated with AT III and 4 patients (36%) in the control group received allogeneic blood perioperatively. No patients in either group required transfusion of platelets or fresh frozen plasma.
3 Ann Thorac Surg ROSSI ET AL 1999;68: ANTITHROMBIN III IN CORONARY SURGERY 2233 Table 2. Comparison of Operating Parameters Group A Group B t Test Operation time (min) ns Clamping time (min) ns CPB time (min) ns Chest closure time (min) ns Bleeding (ml/24 h) p 0.05 Heparin (mg) p 0.05 Protamine (mg) p 0.05 Surgical re-exploration 0 patients 0 patients 2 ns Transfusion 1 patient 4 patients 2 ns Table 4. Hematocrit Variations HT % Group A Group B Newman-Keuls Group A B Baseline 42 4 a 42 4 a ns Before CPB 33 6 a 30 5 a ns End CPB 26 3 a 26 3 a ns End operation 30 4 a 32 3 a ns 1st postoperative day 34 4 a 35 4 a ns a ANOVA factor time within group: p HT hematocrit; CPB cardiopulmonary bypass; ns not significant. CPB cardiopulmonary bypass; ns not significant. The chest-tube drainage in the first 24 postoperative hours was significantly greater in the control group than in the group treated with AT III ( ml versus ml, p 0.05). Heparin intraoperative requirement was significantly lower in the patients treated with AT III than in the patients of the control group ( mg versus mg, p 0.05) (Table 2). Whereas in group A there was no need for additional heparin doses, in 7 patients of group B (67%) additional heparin doses were required to keep ACT values above 480 seconds. After heparin and during CPB, ACT values were significantly higher in the treated group than in the untreated group (Table 3). The total amount of protamine administered to the patients of the AT III group was significantly lower than that administered to the patients of group B ( mg versus mg, p 0.05) (Table 2). Hematocrit values changed significantly at the scheduled times in each group, but the differences between the two groups were not statistically significant (Table 4). In both groups, PT, aptt, and fibrinogen values varied significantly but similarly at the end of operation and at the first postoperative day (Table 5). Platelets significantly decreased at the end of the operation in both groups (172,000 40,000 versus 216,000 59,000 in group A; 142,000 35,000 versus 210,000 56,000 in group B) and returned to the preoperative values at the first postoperative day in both groups without statistically Table 3. ACT Variations ACT(s) Group A Group B Newman-Keuls Group A B Baseline a a ns Before CPB a a p 0.05 Start CPB a a p 0.01 End CPB a a p 0.01 After protamine a a ns End operation a a ns 1st h in ICU a a ns a ANOVA factor time within group: p ACT Activated coagulation time; CPB cardiopulmonary bypass; ICU intensive care unit; ns not significant. significant differences between the two groups at the three scheduled times (Table 5). The data about the hemocoagulative markers discussed in the present study are reported in Figures 1 and 2. Preoperative AT III levels were at the lower limits of the normal range in both groups (75.3% 4.1 in group A; 76.1% 7.5 in group B). No significant change in AT III was shown at the scheduled times in the control group except for a small decrease at the end of CPB (68.1% 7.4). On the contrary, AT III increased significantly in the treated group compared to the preoperative value (p 0.001). In group A, AT III values showed a sharp rise (102.2% 30.1) after the administration of AT III concentrates before entering CPB, which was maintained during the following times except for a small decrease at the end of CPB (90.5% 18.3). In the treated group, AT III values, except for the preoperative value, were always significantly higher than AT III values of the untreated group (p 0.01). In both groups, TAT, F 1.2 and d-dimers showed important changes at the different times of the study (p 0.001). In fact, all three markers showed a sharp rise at the end of CPB and these levels were maintained at the end of the operation. Levels of TAT increased significantly more in the control group than in the AT III group at the end of CPB ( g/l versus g/l, p 0.01) and at the end of operation ( g/l versus g/l, p 0.01). A similar course was seen with F 1.2, which increased more in the untreated patients at the end of CPB ( nm/ml versus nm/ml, p 0.01) and at the end of operation ( nm/ml versus nm/ml, p 0.01). Variations in d-dimers were not significantly different between treated and untreated patients at the end of CPB ( ng/ml versus ng/ml) and at the end of the operation ( ng/ml versus ng/ml), even if they increased more in the untreated patients. Whereas TAT and d-dimers levels remained significantly higher than the preoperative values (p 0.05) in both groups at the first postoperative day, F 1.2 returned to the preoperative values. At the first postoperative day, TAT, d-dimers and F 1.2 levels did not differ significantly between the groups.
4 2234 ROSSI ET AL Ann Thorac Surg ANTITHROMBIN III IN CORONARY SURGERY 1999;68: Table 5. Coagulation Data Group A Group B Newman-Keuls Group A B Platelets mm 3 Baseline b b ns End of operation b b ns 1st postoperative day b b ns PT % Baseline b b ns End of operation 68 6 b 65 8 b ns 1st postoperative day 72 9 b 74 5 b ns aptt second Baseline 29 8 a 32 2 b ns End of operation 29 9 a 43 5 a ns 1st postoperative day a 47 7 a ns Fibrinogen mg/dl Baseline b b ns End of operation b b ns 1st postoperative day b b ns a ANOVA factor time within group: p b ANOVA factor time within group: p aptt activated partial thromboplastin time; PT prothrombin time. Comment The use of CABG operations is increasing due to the progressive spreading of atherosclerotic coronary disease and to a better diagnosis of the patients at risk. The patient with unstable angina on preoperative heparin treatment might come to the operation with a poor coagulative system, because a prolonged heparin treatment causes a decrease of AT III levels. Cofactor deficit might lead to an inadequate systemic anticoagulation during CPB and to the phenomena of consumptive coagulopathy due to excessive thrombin activation [5, 6]. This study showed the effectiveness of an intraoper- Fig 1. AT III (A) and TAT (B) comparison between the groups at the times of the study. (**Newman-Keuls A B p AT III antithrombin III; TAT thrombin-antithrombin complex.) Fig 2. F 1.2 (A) and d-dimers (B) comparison between the groups at the times of the study. (**Newman-Keuls A B p F 1.2 fragment 1.2 of prothrombin.)
5 Ann Thorac Surg ROSSI ET AL 1999;68: ANTITHROMBIN III IN CORONARY SURGERY 2235 Fig 3. The scheme shows AT III sites of action in the final pathway of the coagulation system, localizing TAT, F1.2, and d-dimers within the cascade. (AT III antithrombin III; F 1.2 fragment 1.2 of prothrombin; TAT thrombin-antithrombin complex.) ative AT III concentrates treatment in patients with unstable angina undergoing coronary artery bypass surgery. The group of patients treated with AT III concentrates showed a better intraoperative and postoperative coagulative pattern and expression of a more correct functioning of the hemostatic balance. In fact, in all the treated patients, standard heparinization proved to be effective to keep the optimal anticoagulation during CPB, as confirmed by ACT values constantly above 480 seconds. Both groups have AT III preoperative levels in the inferior part of the normal range because of the prolonged preoperative heparin treatment. The administration of AT III concentrates to group A restores adequate levels of AT III, allowing heparin to be the antagonist of thrombin and to stop the coagulative processes triggered by CPB. In group B, heparin results were not as effective, because AT III preoperative levels were not sufficient to obtain a complete anticoagulation during CPB. So, to keep adequate ACT, extra doses of heparin are required. If lower concentrations of AT III reduce heparin effect, higher levels of free thrombin are produced, even if more heparin is empirically administered. Free thrombin is able to activate a consumptive coagulopathy. The behavior of TAT, F 1.2, and d-dimers confirms this hypothesis. These factors are strictly linked to thrombinantithrombin III interaction as shown in Figure 3. In the treated group, F 1.2 increases significantly less after CPB, so less thrombin has been generated; this suggests that AT III concentrates should be able to reestablish a better hemostatic balance, playing a protective role against consumptive coagulopathy, even if consumptive coagulopathy is not completely prevented. The TAT increase in the control group at the end of CPB and at the end of the operation suggests that more free thrombin was produced in this group during CPB, which somehow consumes more available AT III. Though not significantly, d-dimers increased more in the untreated group after CPB. This shows that a higher level of free thrombin was generated, which was able to act on fibrinogen. Heparin worked better in group A, as confirmed by the fact that the treated patients did not need any extra heparin dose to keep ACT above 480 seconds. If heparin administration during the operation was increased, it was possible to obtain ACT above 480 seconds in the untreated patients too. This was probably due to the antithrombinic action of heparin through the heparinic cofactor II. However, if more heparin is given, there are more possibilities to find it bonded to the endothelium or in the residual volume in the CPB circuit reinfused after the operation. This might cause an increased risk of heparin rebound and motivate a trend to administer higher doses of protamine, based on the clinical observation of a wet patient. In fact, more protamine was administered to, and more blood loss and transfusion requirements were observed in, the untreated group. Protamine itself can act as anticoagulant, inhibiting the thrombin, when administered in excessive doses or in the absence of heparin. In our institution, the majority of patients affected by unstable angina are treated with subcutaneous heparin, beta blockers, and nitrates po. We excluded patients treated with intravenous nitroglycerin because of the possible induction of heparin resistance. The therapy with intravenous heparin and intravenous nitrates is limited to severe unstable angina, with indication for urgent revascularization. This study shows clearly that intraoperative administration of AT III concentrates in patients with unstable angina having preoperative heparin treatment allows an adequate anticoagulation during CPB and avoids, though incompletely, the activation of the coagulative cascade. The high cost of AT III concentrates should be considered, but it should be compared with the costs of an allogeneic blood transfusion or surgical reexploration. The risk of virally transmitted diseases can not be completely excluded, although it is very low, because of the safe techniques of purification in selected donor pools. Patients with unstable angina having preoperative heparin treatment undergoing coronary surgery in CPB should be always considered as patients at higher risk of bleeding, and the surgical team must be aware of their possible coagulative derangement. References 1. Naunheim KS, Fiore AC, Arango DC, et al. Coronary artery bypass grafting for unstable angina pectoris: risk analysis. Ann Thorac Surg 1986;47: Collins P, Fox KM. Pathophysiology of angina. Lancet 1990;1: Neri Serneri GG, Gensini GF, Poggesi L, et al. Effect of heparin or aspirin in reduction of myocardial ischemia in refractory unstable angina. Lancet 1990;335: Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1989; 319: Lidon RM, Theroux P, Robitaille D. Antithrombin III plasma activity during and after prolonged use of heparin in unstable angina. Thromb Res 1993;72:23 32.
6 2236 ROSSI ET AL Ann Thorac Surg ANTITHROMBIN III IN CORONARY SURGERY 1999;68: Dietrich W, Spannagl M, Schramm W, et al. The influence of preoperative anticoagulation heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 102: Anderson EF. Heparin resistance prior to cardiopulmonary bypass. Anesthesiology 1986;64: Karski J, Teasdale S, Norman P, et al. Heparin requirements before and during CPB in patients receiving preoperative intravenous heparin. Anesthesiology 1994;77:A Soloway HB, Christiansen TW. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin III deficient patient. Am J Clin Pathol 1980;73: Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76: Buller H, Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrates. Am J Med 1989;87(Suppl 3B):44S 48S. 12. Clark P, Walker ID, Neilson F. Coronary artery bypass surgery in patients with inherited antithrombin deficiency. Br J Haematol 1995;90: Lechner K, Kyrle A. Antithrombin III concentrates. Are they clinically useful? Thromb Haemost 1995;3: Menaché B, Grossman BJ, Jackson CM. Antithrombin III: physiology, deficiency and replacement therapy. Transfusion 1992;2: Becker CR, Corrao J, Bovill GE, et al. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990;119: INVITED COMMENTARY This is an interesting study showing a dramatic decrease in the initial heparin dose requirement as well as in heparin requirements during CPB in patients pretreated with ATIII after subcutaneous heparinization. I am much less impressed with reduction of blood loss shown in this study (average of 184 ml over 24 hours). The small number of patients enrolled in this study makes it impossible to evaluate any clinically relevant benefit of ATIII treatment to these patients. Considering the cost of ATIII and concerns about unanswered questions (use of ATIII in cardiac surgical patients not on heparin, use after prolonged IV heparinization, comparison with antifibrinolytics with respect to bleeding), I would wait for large clinical dose finding studies and outcome trials before recommending routine use of ATIII in cardiac patients. Jacek M. Karski, MD Anaesthesia Dept The Toronto Hospital 200 Elizabeth St Toronto, ON M5G 2C4, Canada 1999 by The Society of Thoracic Surgeons /99/$20.00 Published by Elsevier Science Inc PII S (99)
Diagnostic, Technical and Medical
Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX Background
More informationIntraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
More informationComparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery
Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationEffective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)
1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory
More informationThe increasing use of normothermic cardiopulmonary
A Prospective, Randomized Study of Cardiopulmonary Bypass Temperature and Blood Transfusion Paul E. Stensrud, MD, Gregory A. Nuttall, MD, Maria A. de Castro, MD, Martin D. Abel, MD, Mark H. Ereth, MD,
More informationEDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION
EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationIntraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL
Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage
More informationTSDA ACGME Milestones
TSDA ACGME Milestones Short MW and Edwards JA. Assessing resident milestones using a CASPE March 2012 Short MW and Edwards JA. Assessing resident milestones using a CASPE March 2012 Short
More informationOPCAB IS NOT BETTER THAN CONVENTIONAL CABG
OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA
More informationModern Transfusion Management in Cardiovascular Surgery
Modern Transfusion Management in Cardiovascular Surgery Linda Shore-Lesserson, M.D. Professor of Anesthesiology Albert Einstein School of Medicine Montefiore Medical Center Bronx, New York Patient Blood
More informationCardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center
The fellowship in Cardiothoracic Anesthesia at the Beth Israel Deaconess Medical Center is intended to provide the foundation for a career as either an academic cardiothoracic anesthesiologist or clinical
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationHemodialysis (HD) has improved the prospects of. Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients
CARDIOVASCULAR Sonoclot Analysis in Cardiac Surgery in Dialysis- Dependent Patients Toshihiko Shibata, MD, PhD, Yasuyuki Sasaki, MD, PhD, Koji Hattori, MD, PhD, Hidekazu Hirai, MD, Mitsuharu Hosono, MD,
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationTRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006
TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.
More informationFibrinogen and Bleeding in Cardiac Surgery:
From the Department of Cardiovascular Surgery and Anesthesia Sahlgrenska University Hospital and Department of Molecular and Clinical Medicine Institute of Medicine, Sahlgrenska Academy University of Gothenburg
More informationConventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury?
Conventional CABG Or On Pump Beating Heart: A Difference In Myocardial Injury? Kornelis J. Koopmans Medical Center Leeuwarden Leeuwarden, The Netherlands I have no disclosures Disclosures Different techniques
More informationHow can ROTEM testing help you in cardiac surgery?
How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential
More informationHemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands
Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins
More informationOn-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery
On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationNavigating the Dichotomies Between Literature and Your Clinical Practice
Navigating the Dichotomies Between Literature and Your Clinical Practice Robert Groom, CCP, FPP Cardiovascular Institute at Maine Medical Center Disclosures No relevant conflicts related to this presentation
More informationBlood Management of the Cardiac Patient in the Postoperative Period
Blood Management of the Cardiac Patient in the Postoperative Period Al Stammers, MSA, CCP, Eric Tesdahl, PhD Andy Stasko MS, CCP, RRT, Linda Mongero, BS, CCP, Sam Weinstein, MD, MBA Goal To examine the
More informationTEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage
TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage Kevin Fleming, CCP; Roberta E. Redfern, PhD; Rebekah L. March, MPH; Nathan Bobulski, CCP; Michael Kuehne, PhD, PA-C; John
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationComparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used in Coagulation Testing
Coagulation and Transfusion Medicine / GLASS VS PLASTIC IN HEMOSTASIS TESTING Comparison of Samples Obtained From 3.2% Sodium Citrate Glass and Two 3.2% Sodium Citrate Plastic Blood Collection Tubes Used
More informationActivation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin
Activation of the Protein C System During Cardiopulmonary Bypass With and Without Aprotinin Ron G. H. Speekenbrink, MD, Rogier M. Bertina, PhD, Francisco España, PhD, Charles R. H. Wildevuur, MD, PhD,
More informationReinfusion of autologous blood after cardiac surgery
Safety and Efficacy of Perioperative Cell Salvage and After Coronary Artery Bypass Grafting: A Randomized Trial Gavin J. Murphy, MD, FRCS, Simon M. Allen, FRCS, Jonathon Unsworth-White, FRCS, C. Terence
More informationAnticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT
Haemostasis Thrombosis Phases Endogenous anticoagulants Stopping blood loss Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT Vascular Platelet
More informationProspective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz,
More informationIMPROVE PATIENT OUTCOMES AND SAFETY IN ADULT CARDIAC SURGERY.
Clinical Evidence Guide IMPROVE PATIENT OUTCOMES AND SAFETY IN ADULT CARDIAC SURGERY. With the INVOS cerebral/somatic oximeter An examination of controlled studies reveals that responding to cerebral desaturation
More information'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'
'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More information2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older)
2016 Physician Quality Reporting System Data Collection Form: Coronary Artery Bypass Graft (CABG) (for patients aged 18 years and older) IMPORTANT: Any measure with a 0% performance rate (100% for inverse
More informationCardiopulmonary Support and Physiology
CSP Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass Sandra Dial, MD, MSc, Eugene Delabays, MD, Martin Albert, MD,
More informationEmergency surgery in acute coronary syndrome
Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
More informationOriginal Article Post-Operative Bleeding Pak Armed Forces Med J 2014; 1(1): S13-18
Original Article Post-Operative Bleeding Pak Armed Forces Med J 2014; 1(1): S13-18 COMPARISON OF DIFFERENT DOSES OF TRANEXAMIC ACID ON POST-OPERATIVE BLEEDING IN PATIENTS OF CABG SURGERY Fakher-e-Fayaz,
More informationThromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH
Thromboelastograph (TEG ) Utilization in Blood Management Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH TEG Hemostasis System ROTEM Delta Whole blood Hemostasis Analyzer Personalized
More informationECMO vs. CPB for Intraoperative Support: How do you Choose?
ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon
More informationIs the patient at risk for blood loss of 1000 mls? Avoid these Guidelines. Avoid these Guidelines. Yes. Yes. Yes. Yes. Yes
Clinical Guidelines Acute rmovolemic Hemodilution Guidelines for Cardiac Surgery Department of Anesthesiology and Perioperative Medicine Date: 12-30-2012 Is the patient at risk for blood loss of 1000 mls?
More informationIntra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman
Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial
More informationADMINISTRATIVE CLINICAL Page 1 of 6
ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationTransfusions in Acute Care Too Little?
Transfusions in Acute Care Too Little? Keyvan Karkouti MD FRCPC MSc Associate Professor Department of Anesthesia; Department of Health Policy, Management, and Evaluation; University of Toronto Scientist
More informationBleeding, Coagulopathy, and Thrombosis in the Injured Patient
Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial
More informationIncidence and pattern of Thrombocytopenia in cardiac surgery patients
1019 ORIGINAL ARTICLE Incidence and pattern of Thrombocytopenia in cardiac surgery patients Mohammad Hamid, Mohammad Irfan Akhtar, Hamid Iqil Naqvi, Khalid Ahsan Abstract Objective: To observe the incidence
More informationPatient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto
Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto Disclosures Relevant relationships with commercial entities: Octapharma, CSL Behring
More informationCORONARY ARTERY BYPASS GRAFT
CORONARY ARTERY BYPASS GRAFT Coronary artery disease develops because of hardening of the arteries (arteriosclerosis) that supply blood to the heart muscle. In the diagnosis of coronary artery disease,
More informationRandomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
More informationIntraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding
Intraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding Robert E. Helm, MD, John D. Klemperer, MD, Todd K. Rosengart, MD, Jeffrey P. Gold, MD, Powers
More informationAdvances in Transfusion and Blood Conservation
Advances in Transfusion and Blood Conservation Arman Kilic, MD Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, Baltimore, MD No relevant financial relationships to disclose.
More informationHemostasis Alterations in Patients With Acute Aortic Dissection
ADULT CARDIAC Hemostasis Alterations in Patients With Acute Aortic Dissection Domenico Paparella, MD, Crescenzia Rotunno, BSc, Pietro Guida, PhD, Pietro Giorgio Malvindi, MD, Giuseppe Scrascia, MD, Micaela
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Activated partial thromboplastin time abnormality, perioperative approach to, 104 105 Acute kidney injury, perioperative, 89 99 early
More informationInter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationManaging Coagulopathy in Intensive Care Setting
Managing Coagulopathy in Intensive Care Setting Dr Rock LEUNG Associate Consultant Division of Haematology, Department of Pathology & Clinical Biochemistry Queen Mary Hospital Normal Haemostasis Primary
More informationCHAPTER-I MYOCARDIAL INFARCTION
CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationPreparing for Patients at High Risk of Transfusion
18/10/2017 Preparing for Patients at High Risk of Transfusion Jane Ottens. B.Sc., CCP ( Aust) Ashford Hospital, South Australia Preparing for Patients at High Risk of Transfusion Jane Ottens. B.Sc., CCP
More informationSafety of Same-Day Coronary Angiography in Patients Undergoing Elective Aortic Valve Replacement
Safety of Same-Day Coronary Angiography in Patients Undergoing Elective Aortic Valve Replacement Kevin L. Greason, MD, Lars Englberger, MD, Rakesh M. Suri, MD, PhD, Soon J. Park, MD, Charanjit S. Rihal,
More informationDisseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department
Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic
More informationCardiac surgery is associated with a high incidence of
Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit Reduces Blood Transfusion After Coronary Artery Surgery Subramaniam Balachandran, FRCA, Michael H. Cross, FRCA, Sivagnanam Karthikeyan,
More informationDeclaration of conflict of interest NONE
Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages
More informationInteresting Cases - A Case Report: Renal Cell Carcinoma With Tumor Mass In IVC And Heart. O Wenker, L Chaloupka, R Joswiak, D Thakar, C Wood, G Walsh
ISPUB.COM The Internet Journal of Thoracic and Cardiovascular Surgery Volume 3 Number 2 Interesting Cases - A Case Report: Renal Cell Carcinoma With Tumor Mass In IVC And Heart O Wenker, L Chaloupka, R
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Ablation, radiofrequency, anesthetic considerations for, 479 489 Acute aortic syndrome, thoracic endovascular repair of, 457 462 aortic
More informationCoagulation BEFORE Surgery
Coagulation BEFORE Surgery Lorenzo ALBERIO Médecin chef Hématologie générale et Hémostase Service et Laboratoire centrale d Hématologie CHUV, Lausanne Outline 1. Pre-op testing 2. Ongoing anticoagulation
More informationThromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation
Open Journal of Organ Transplant Surgery, 2013, 3, 13-17 http://dx.doi.org/10.4236/ojots.2013.31003 Published Online February 2013 (http://www.scirp.org/journal/ojots) Thromboelastography Use in the Perioperative
More informationWarfarin Cessation Before Cardiopulmonary Bypass: Lessons Learned from a Randomized Controlled Trial of Oral Vitamin K
Warfarin Cessation Before Cardiopulmonary Bypass: Lessons Learned from a Randomized Controlled Trial of Oral Vitamin K Richard P. Whitlock, MD, Mark A. Crowther, MD, Theodore E. Warkentin, MD, Mary-Helen
More informationUseful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication vs Benefit? Mortality? Morbidity?
Preoperative intraaortic balloon counterpulsation in high-risk CABG Stefan Klotz, M.D. Preoperative IABP in high-risk CABG Questions?? Useful? Definition of High-risk? Pre-OP/Intra-OP/Post-OP? Complication
More information2012, Görlinger Klaus
Gerinnungsmanagement der Gegenwart - wie gehen wir heute vor? 25. Allander Gerinnungsrunde am 15. März 2012 Klaus Görlinger Universitätsklinikum Essen klaus@goerlinger.net CSL Behring GmbH Octapharma AG
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationClinical Implications of the Impact of Serum Tissue Factor Levels after Trauma
Clinical Implications of the Impact of Serum Tissue Factor Levels after Trauma Ian E. Brown, MD, PhD, and Joseph M. Galante MD, FACS Formatted: Font: 16 pt, Bold Formatted: Centered Formatted: Font: Bold
More informationSredišnja medicinska knjižnica
Središnja medicinska knjižnica Petričević M., Biočina B., Boban M., Zrno Mihaljević M., White A., Rotim C., Subašić A., Miličić Davor. (2015) Clinical relevance and practical value of platelet function
More informationOPCABG for Full Myocardial Revascularisation How we do it
OPCABG for Full Myocardial Revascularisation How we do it 28 th SHA Conferance Dr.Farouk Oueida Head of Cardiac Surgery Dept. SBCC-Dammam KSA The Less Invasive CABG Full Revascularisation Full Sternotomy
More informationcoagulation defect of paracetamol-induced hepatic necrosis
Gut, 1974, 15, 89-93 A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis B. G. GAZZARD, R. CLARK, V. BORIRAKCHANYAVAT, AND ROGER WILLIAMS From the Liver
More informationVehicle ACT. 180 min. Time After Current Initiation (min) 180 min. Vehicle. UFH (75 U/kg) Anti-Factor Xa. Time After Current Initiation (min)
Efficacy of, a Rationally-Engineered Low-Molecular-Weight Heparin, in a Canine Model of Arterial Thrombosis Ian D Fier, Mark A Nedelman, J Luis Guerrero, Ganesh Venkataraman, and Yi Wei Qi Momenta Pharmaceuticals,
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationDiabetes is a well-established risk factor for atherosclerotic
Coronary Artery Bypass Grafting in Type II Diabetic Patients: A Comparison Between Insulin-Dependent and Non-Insulin-Dependent Patients at Short- and Mid-Term Follow-Up Nicola Luciani, MD, Giuseppe Nasso,
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationStudies, mainly performed in patients undergoing coronary artery bypass
Parolari et al Cardiopulmonary Support and Physiology Increased prothrombotic state lasting as long as one month after on-pump and off-pump coronary surgery Alessandro Parolari, MD, PhD, a Luciana Mussoni,
More informationPreoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?
Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery? Damien J. LaPar MD, MSc, James M. Isbell MD, MSCI, Jeffrey B. Rich MD, Alan M. Speir MD, Mohammed
More informationCASE IN... Anticoagulation: When to Start,When to Stop. The management of patients who require an. Meet Tracey. Anticoagulation
Anticoagulation: When to Start,When to Stop Ebtisam Bakhsh, MD; and James D. Douketis, MD, FRCPC Presented at McMaster University s Thrombosis and Hematology Update, October 2006. CASE IN... Anticoagulation
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationPharmacologic impairment of platelet membrane glycoprotein
Emergency Coronary Artery Bypass Graft Surgery in Abciximab-Treated Patients John H. Lemmer, Jr, MD, Mark T. Metzdorff, MD, Albert H. Krause, Jr, MD, M. Alan Martin, MD, J. Edward Okies, MD, and Jon G.
More informationLearning from errors. A Arrivi, 1 G Tanzilli, 1 L Tritapepe, 2 G Mazzesi, 3 E Mangieri 1
Learning from errors Undetected acute aortic dissection in a patient referred for primary coronary angioplasty: a successful treatment of perioperative bleeding after abciximab administration A Arrivi,
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationMANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR
MANAGEMENT OF OVERANTICOAGULATION AND PREOPERATIVE MANAGEMENT OF WARFARIN DOSE 1. GUIDELINES FOR THE MANAGEMENT OF AN ELEVATED INR 1.1 Time to lower INR Prothrombinex-VF - 15 minutes Fresh Frozen Plasma
More informationEffects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass
Effects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass Claes Aren, M.D., Kurt Feddersen, M.D., and Kjell Ridegran, M.D. ABSTRACT The effects of infusion
More informationChanging profile of patients undergoing redo-coronary artery surgery q
European Journal of Cardio-thoracic Surgery 21 (2002) 205 211 www.elsevier.com/locate/ejcts Changing profile of patients undergoing redo-coronary artery surgery q Frans M. van Eck, Luc Noyez*, Freek W.A.
More informationJournal of the American College of Cardiology Vol. 33, No. 6, by the American College of Cardiology ISSN /99/$20.
Journal of the American College of Cardiology Vol. 33, No. 6, 1999 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00061-3 for Prediction
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationPRACTICE guidelines are systematically developed recommendations that assist the
Embargoed for release until approved by ASA House of Delegates. No part of this document may be released, distributed or reprinted until approved. Any unauthorized copying, reproduction, appropriation
More informationResults and Treatment Strategy for Patients Undergoing Emergent Coronary Artery Bypass Grafting
Original Article Results and Treatment Strategy for Patients Undergoing Emergent Coronary Artery Bypass Grafting Stefan Christiansen, MD, and Rüdiger Autschbach, MD Background: Emergent coronary artery
More informationReversal of Anticoagulants at UCDMC
Reversal of Anticoagulants at UCDMC Introduction: Bleeding complications are a common concern with the use of anticoagulant agents. In selected situations, reversing or neutralizing the effects of an anticoagulant
More informationSetting The setting was a hospital. The economic study was carried out in Australia.
Coronary artery bypass grafting (CABG) after initially successful percutaneous transluminal coronary angioplasty (PTCA): a review of 17 years experience Barakate M S, Hemli J M, Hughes C F, Bannon P G,
More informationTransfusion practice in coronary artery bypass surgery in Denmark: a multicenter audit,
doi:10.1510/icvts.2007.154401 Interactive CardioVascular and Thoracic Surgery 6 (2007) 623 627 Institutional report - Cardiac general www.icvts.org Transfusion practice in coronary artery bypass surgery
More informationSurgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi
Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi SC Cardiochirurgia U Universita degli Studi di Torino PORT-ACCESS TECNIQUE Reduce surgical trauma Minimize disruption of the chest wall
More informationGoals and Objectives. Assessment Methods/Tools
CA-2 CARDIOTHORACIC ANESTHESIA ROTATION Medical Center Fairview (UMMC) Rotation Site Director: Drs. Ioanna Apostolidou & Douglas Koehntop Rotation Duration: 6 weeks Introduction: The overall goal of the
More informationPROTAMINE IS USED to reverse heparin after termination
A Pharmacokinetic Model for Protamine Dosing After Cardiopulmonary Bypass Michael I. Meesters, MD,* Dennis Veerhoek, CCP, Jan R. de Jong, MD,* and Christa Boer, PhD* Objective: This study investigated
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More information